March 12, 2024

Amplify’s Shares Rise on Southern California Oil Sheen Update

Shares in Amplify Energy (NYSE: AMPY) rose nearly 20% in intraday trading on Monday after the company made two separate statements concerning an oil sheen that had appeared off the coast of Huntington Beach. Amplify said it was cooperating with the US Coast Guard in its investigations, and later announced it was “confident that the… [Read More]
March 12, 2024

Amplify’s Shares Rise on Southern California Oil Sheen Update

Shares in Amplify Energy (NYSE: AMPY) rose nearly 20% in intraday trading on Monday after the company made two separate statements concerning an oil sheen that had appeared off the coast of Huntington Beach. Amplify said it was cooperating with the US Coast Guard in its investigations, and later announced it was “confident that the… [Read More]
March 12, 2024

PRISM Market Moves on Tuesday: Oracle Outperforms; Southwest, AA and Boeing Drop

US equities are trading mostly higher on Tuesday at midday after a depressed session on Monday. Nvidia ($NVDA) is outperforming among the big tech names and software, credit cards, household products, department stores, restaurants, and casinos are also strong. Underperformers include airlines, telecoms, energy, utilities, precious metals, and banks. Treasuries are weaker, the Dollar index… [Read More]
March 12, 2024

Plant Power: Manitoba Harvest Launches Hemp-Based Breakfast Oatmeal

Tilray Brands (Nasdaq: TLRY) subsidiary and leading hemp foods manufacturer, Manitoba Harvest, has expanded its plant-based breakfast portfolio with the addition of instant Superseed Oatmeal. The company’s new oatmeal product contains hemp heart and is available in Original, Maple & Brown Sugar, and Apple & Cinnamon flavors. The company’s Superseed Oatmeal is packed with 10g… [Read More]
March 12, 2024

BioNxt Advances MS Treatment with Innovative Dissolvable Film Drug Delivery

BioNxt Solutions Inc. (OTCQB: BNXTF) has completed a comparative pharmacokinetic (PK) study of its oral dissolvable film (ODF) based proprietary Cladribine product for the treatment of Multiple Sclerosis (MS). BioNxt is developing a proprietary hybrid-generic ODF Cladribine dosage form for the MS market. In February 2023, the company reported positive results from a preclinical oral… [Read More]
March 11, 2024

Nvidia Sued Over AI’s Use of Copyrighted Works

As artificial intelligence (AI) continues its evolution and integration into almost every sector, the question of content ownership continues to be raised. This week, Nvidia ($NVDA), a prominent player in the AI field, has found itself facing legal action as authors allege copyright infringement facilitated by its AI technology. The lawsuit addresses Nvidia’s utilization of… [Read More]
March 11, 2024

Accelerated Approval Pathway for Mesoblast’s Heart Failure Therapeutic

The FDA supports an accelerated approval pathway for Mesoblast Limited’s (Nasdaq: MESO) rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). “We are very pleased with FDA’s feedback that the presented results from our pivotal study of… [Read More]